‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
MarketWatch · 2026-10-13 23:37 · 资讯
The Federal Trade Commission and seven states say Shkreli should be held in contempt
The Federal Trade Commission and seven states say Shkreli should be held in contempt
话题：#‘Pharma Bro’ Martin Shkreli is in
墨子AI
